Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Debt (2024 - 2025)

Historic Total Debt for Karyopharm Therapeutics (KPTI) over the last 2 years, with Q4 2025 value amounting to $115.8 million.

  • Karyopharm Therapeutics' Total Debt rose 2241.16% to $115.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $115.8 million, marking a year-over-year increase of 2241.16%. This contributed to the annual value of $115.8 million for FY2025, which is 2241.16% up from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Total Debt stood at $115.8 million, which was up 2241.16% from $96.4 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Total Debt ranged from a high of $115.8 million in Q4 2025 and a low of $93.5 million during Q2 2024